Lord, Abbett & Co
CALA

Lord, Abbett & Co’s Calithera Biosciences, Inc CALA Stock Holding History

Lord, Abbett & Co’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-19,228
Closed -$3.21M – 925
2017
Q4 		$3.21M Sell
19,228
-12,285
-39% -$3.15M 0.01% 813
2017
Q3 		$9.93M Buy
31,513
+6,622
+27% +$2.09M 0.03% 636
2017
Q2 		$7.39M Buy
24,891
+9,853
+66% +$2.64M 0.02% 696
2017
Q1 		$3.47M Buy
+15,038
New +$2.6M 0.01% 792

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co's CALA Position: Q1 2018 in Review

Lord, Abbett & Co sold out of Calithera Biosciences, Inc (CALA) in Q1 2018, closing a stake of 19,228 shares — an estimated $3.21M sold.

Lord, Abbett & Co first reported a position in CALA in Q1 2017 and held it in 4 quarters. The position peaked at $9.93M in Q3 2017. 100 funds tracked by Wall St. Rank hold CALA as of Q1 2018.

  • Lord, Abbett & Co reported no remaining Calithera Biosciences, Inc position as of Q1 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 19,228 Calithera Biosciences, Inc shares in Q1 2018, an estimated $3.21M.
  • Lord, Abbett & Co first reported a position in Calithera Biosciences, Inc in Q1 2017 and held it in 4 quarters.
  • Lord, Abbett & Co's Calithera Biosciences, Inc position peaked at $9.93M in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2018.

Based on Lord, Abbett & Co's 13F filing for Q1 2018, filed 15 May 2018.